<DOC>
	<DOCNO>NCT01353404</DOCNO>
	<brief_summary>The purpose study evaluate bioequivalence Lipidil® Supra ( fenofibrate 160mg ) versus SYO-0805 ( fenofibrate 65mg ) single dose oral administration .</brief_summary>
	<brief_title>Relative Bioavailability Study Lipidil® Supra ( Fenofibrate 160mg ) Versus SYO-0805 ( Fenofibrate 65mg )</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Healthy adult 2050 year age Weight 55kg within ±20 % IBW ( Ideal Body Weight ) Voluntary write informed consent History presence significant renal , neurologic , pulmonary , endocrine , hematology , oncology , urologic , cardiovascular , musculoskeletal psychiatric disease Drug allergies fenofibrate Recent history evidence drug abuse Recent participation ( within 2months ) clinical study Recent donation blood ( within 2months ) plasma ( within 1months )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>